Article Details
Retrieved on: 2023-01-10 23:32:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
PARP inhibitor Lynparza, co-developed with AstraZeneca, provided $825 million and cancer drug Lenvima generated $660 million by the end of the ...
Article found on: www.biospace.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here